PT  - JOURNAL ARTICLE
AU  - Safarzadeh, Meysam
AU  - Herbert, Carly
AU  - Wong, Steven Koon
AU  - Stamegna, Pamela
AU  - Guilarte-Walker, Yurima
AU  - Wright, Colton
AU  - Suvarna, Thejas
AU  - Nowak, Chris
AU  - Kheterpal, Vik
AU  - Pandey, Shishir
AU  - Wang, Biqi
AU  - Lin, Honghuang
AU  - O’Connor, Laurel
AU  - Hafer, Nathaniel
AU  - Luzuriaga, Katherine
AU  - Manabe, Yuka
AU  - Broach, John
AU  - Zai, Adrian H
AU  - McManus, David D
AU  - Du, Xian
AU  - Soni, Apurv
TI  - Automated Classification of At-home SARS-CoV-2 Lateral Flow Assay Test Results using Image Matching and Transfer Learning: multiple-pipeline study
AID  - 10.1101/2024.01.04.24300836
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.01.04.24300836
4099  - http://medrxiv.org/content/early/2024/01/04/2024.01.04.24300836.short
4100  - http://medrxiv.org/content/early/2024/01/04/2024.01.04.24300836.full
AB  - Introduction Rapid antigen testing for SARS-CoV-2 is an important tool for the timely diagnosis of COVID-19, especially in at-home settings. However, the interpretation of test results can be subjective and prone to error. We describe an automated image analysis pipeline to accurately classify test types and results without human intervention using a dataset of 51,274 rapid antigen test images across three distinct test card brands.Methods The proposed method classifies participant-submitted images into four categories: positive for SARS-CoV-2, negative for SARS-CoV-2, invalid/uncertain, and unclassifiable. The model includes four stages: test card classification and region of interest detection using image-matching algorithms, elimination of invalid results using a developed Siamese neural network, and test result classification using transfer learning.Results The model accuracy was very good for test-card classification (100%), region of interest detection (83.5%), and identification of invalid results ranging from 95.6% to 100% for different test types. Performance of the model for test result classification varied by tests; the model’s sensitivity, specificity, and precision for Abbott BinaxNOW™ was 0.761, 0.989, and 0.946, BD Veritor™ At-Home COVID-19 Test was 0.955, 0.993, and 0.877, and for QuickVue® At-Home OTC COVID-19 Test was 0.816, 0.988, and 0.930.Conclusion The proposed method improved the interpretation of rapid antigen tests, particularly in invalid result detection compared to human-read, and offers a great opportunity for standardization of rapid antigen test interpretation and for providing feedback to participants with invalid tests.Competing Interest StatementThe authors have declared no competing interest.Funding StatementDr. McManus is supported by NHLBI grants R01HL155343, R01HL141434, R33HL158541, and U54HL143541. Dr. McManus reports receiving research support (either grants or material) from Apple Computer, Bristol-Myers Squibb, Boehringer-Ingelheim, Pfizer, Samsung, Flexcon, Philips Healthcare, and Biotronik; consultancy fees from Bristol-Myers Squibb, Pfizer, Flexcon, Avania, NAMSA, Fitbit, and Heart Rhythm Society (for editorial work).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics IRB of the University of Massachusetts Chan Medical School gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors